Tata Institute develops Rs 100 tablet which stops cancer recurrence - Video
|
Overview
The tablet developed by Tata Memorial Centre (TMC) for preventing cancer recurrence is a significant breakthrough in cancer research and treatment. It offers a potentially affordable solution to a critical aspect of cancer management. However, its availability to the public hinges on the approval process from the Food Safety and Standards Authority of India (FSSAI).
According to the information provided, the tablet is currently awaiting approval from FSSAI. The scientists from Tata Institute of Fundamental Research (TIFR) have applied for approval, indicating a proactive step towards making the tablet accessible to the public. Once FSSAI grants approval, the tablet is expected to be available in the market by June-July.
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751